Pérez TJ, López BL, Cedré FMA, Fernández PZ, Arrieta CB

Language: Spanish
References: 14
Page: 407-413
PDF size: 195.22 Kb.

ABSTRACT

Prenatal exposure to Misoprostol has been associated with the occurrence of terminals transverse defects in upper and lower limbs such as gastroschisis, hypodactilia, and hypoglosia among other birth defects. Misoprostol action mechanism as teratogenic agent has been attributed to a process of vascular disruption with impaired blood flow to the fetus, which results in inadequate perfusion, hypoxia, and hemorrhage.
Here a case of a two-year old boy with terminal transverse defects in his upper and lower limbs is presented. His mother used misoprostol in the first trimester of pregnancy with abortive purposes. This research aims to provide information on misoprostol teratogenic effects and to warn on the possible consequences of continuing pregnancy after using misoprostol as abortifacients, thus, to prevent the birth of children with incompatible birth defects for life, or permanent disability.

REFERENCES

1. Mueller RF, Young ID. Genética y anomalías congénitas. En: Emery´s genética médica. 10ma ed. Madrid: Marbán Libros; 2001.p.223-34.

2. Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol.2009;2:159-68.

3. Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE. Misoprostol embryotoxicity: clinical evaluation of fifteenpatients with arthrogryposis. Am J Med Genet. 2000;95:297-301.

4. Barbero P, Liascovich R, Valdez R, Moresco A. Efecto teratogénico del misoprostol: un estudio prospectivo en Argentina. Arch. Argent. Pediatr. Buenos Aires mayo/jun. 2011;109(3).

5. Da Silva Dal Pizzol T, Tierling VL, Schüler-Faccin L, San-severino MT. Reproductive results associated with misoprostol and other substances utilized for interruption of pregnancy. Eur J Clin Pharmacol. 2005;61(1):71-2.

6. González CH, Marques-Dias MJ, Kim CA, Sugayama SM. Congenital abnormalities in Brazilian children associatedwith misoprostol misuse in 1st trimester of pregnancy. Lancet. 1998;351:624-7.

7. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C. Prenatal exposure to misoprostol and vascular disruption defects:a case-control study. Am J Med Genet. 2000;95:302-6.

8. Philip N, Shannon C, Winikoff B. Misoprostol y teratogenicidad:Revisión de la evidencia. 2002 [Citado: 1 noviembre 2010]. Informe de una reunión organizada por el Population Council New York, New York. Disponible en: http://gynuity.org/downloads/misoprostol_teratogen_sp.pdf

9. Larrandabaru M, Sch Ehlers JA, Macdonald-Reis A, Lemos-Silvera E. The occurrence of Poland and Poland-Moebius syndromes in the same family: further evidence of their genetic component. Clin Dysmorphol.1999;8:93-9.

10. Castilla EE, Orioli IM. Teratogenicity of misoprostol: Data from the Latin- American Collaborative Study of congenital Malformations (ECLAMC). Am J Med Genet.1994; 51:161-2.

11. Genest DR, Di Salvo D, Rosenblat MJ, Holmes LB. Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. Clini Dysmorphol. 1999;8:53-8.

12. Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM,Vargas F, et al. Use of misoprostol during pregnancy and Moebius syndrome in infants. N Engl J Med. 1998;338:1881-5.

13. Armas Y, FleblesTardio L, Boza B. Documento Normativo. Dirección Provincial de Salud, Departamento Materno Infantil. Ciudad Habana. 2009.

14. Obstetricia y perinatología. Diagnóstico y tratamiento. Indicaciones y técnicas de la interrupción del embarazo. Rev Cub Ginec Obstet. 2001;27(3):627-35. Disponible en: http://bvs.sld.cu/revistas/gin/vol27_3_01/gin05301.htm